Hims & Hers Health, Inc. (HIMS)
NYSE: HIMS · Real-Time Price · USD
27.91
-1.48 (-5.04%)
At close: Apr 28, 2026, 4:00 PM EDT
27.92
+0.01 (0.04%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Hims & Hers Health Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Hims & Hers Health stock have an average target of 30.46, with a low estimate of 18 and a high estimate of 68. The average target predicts an increase of 9.14% from the current stock price of 27.91.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Hims & Hers Health stock from 15 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 2 | 2 |
| Buy | 0 | 1 | 1 | 1 | 1 | 2 |
| Hold | 8 | 7 | 8 | 9 | 11 | 11 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Total | 12 | 12 | 13 | 13 | 14 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Initiates $35 | Buy | Initiates | $35 | +25.40% | Apr 24, 2026 |
| B of A Securities | B of A Securities | Hold Maintains $30 → $32 | Hold | Maintains | $30 → $32 | +14.65% | Apr 24, 2026 |
| B of A Securities | B of A Securities | Hold Maintains $21 → $25 | Hold | Maintains | $21 → $25 | -10.43% | Apr 16, 2026 |
| TD Cowen | TD Cowen | Hold Maintains $25 → $23 | Hold | Maintains | $25 → $23 | -17.59% | Mar 27, 2026 |
| Leerink Partners | Leerink Partners | Hold Maintains $18 → $25 | Hold | Maintains | $18 → $25 | -10.43% | Mar 16, 2026 |
Financial Forecast
Revenue This Year
2.81B
from 2.35B
Increased by 19.82%
Revenue Next Year
3.35B
from 2.81B
Increased by 19.23%
EPS This Year
0.58
from 0.51
Increased by 13.49%
EPS Next Year
0.64
from 0.58
Increased by 9.94%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 3.3B | 4.7B | ||||||
| Avg | 2.8B | 3.4B | ||||||
| Low | 2.3B | 2.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 41.0% | 66.6% | ||||||
| Avg | 19.8% | 19.2% | ||||||
| Low | -1.0% | -7.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.28 | 1.05 | |
| Avg | 0.58 | 0.64 | |
| Low | 0.17 | -0.26 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 150.1% | 80.6% | |
| Avg | 13.5% | 9.9% | |
| Low | -67.5% | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.